All In Biotech

Drug Trial Radar · NCT07218796

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,

Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

May 31, 2029

Study completion May 31, 2031

Sponsor

Lead sponsor
SpyGlass Pharma, Inc.Industry
Sponsor type
Industry
First posted
Oct 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Conditions

  • Cataract
  • Glaucoma
  • Ocular Hypertension

Interventions

  • Bimatoprost Implant SystemDrug

    Bimatoprost Implant System used in combination with the SpyGlass IOL

  • SpyGlass IOLDevice

    SpyGlass Intraocular Lens

  • Timolol Maleate Ophthalmic Solution, 0.5%Drug

    Timolol Maleate Ophthalmic Solution, 0.5% BID

  • Commercial IOLDevice

    Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean IOP Reduction from Baseline (mmHg)Time frame: Weeks 2 and 6, and Month 3
  2. BCDVA 20/40 or betterTime frame: Month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • R and R Eye Research, LLC

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.